Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of LZ901 Recombinant Herpes Zoster Vaccine
NCT05750017Phase 1Unknown
- Sponsor
- Beijing Luzhu Biotechnology
- Start
- Mar 2023
- Primary completion
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LZ901 in herpes zoster (HZ) (4 cohorts), sponsored by Beijing Luzhu Biotechnology. Primary endpoints: Solicited Adverse Events, Unsolicited Adverse Events and 3 more. Status: unknown.
02
Drugs
LZ901
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05750017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05750017.